Macrophage secretory IL-1β promotes docetaxel resistance in head and neck squamous carcinoma via SOD2/CAT-ICAM1 signaling

Docetaxel (DTX) combined with cisplatin and 5-fluorouracil has been used as induction chemotherapy for head and neck squamous cell carcinoma (HNSCC). However, the development of acquired resistance remains a major obstacle to treatment response. Tumor-associated macrophages are associated with chemo...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsieh, Ching-Yun, Lin, Ching-Chan, Huang, Yu-Wen, Chen, Jong-Hang, Tsou, Yung-An, Chang, Ling-Chu, Fan, Chi-Chen, Lin, Chen-Yuan, Chang, Wei-Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746909/
https://www.ncbi.nlm.nih.gov/pubmed/36264639
http://dx.doi.org/10.1172/jci.insight.157285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746909/
https://www.ncbi.nlm.nih.gov/pubmed/36264639
http://dx.doi.org/10.1172/jci.insight.157285

Ejemplares similares